Susquehanna International Group
ACAD icon

Susquehanna International Group’s Acadia Pharmaceuticals ACAD Stock Holding History

Susquehanna International Group’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$997K Buy
44,792
+24,140
+117% +$577K ﹤0.01% 7897
2025
Q4 		$552K Sell
20,652
-39,759
-66% -$950K ﹤0.01% 8540
2025
Q3 		$1.29M Sell
60,411
-140,859
-70% -$3.33M ﹤0.01% 6730
2025
Q2 		$4.34M Sell
201,270
-224,200
-53% -$4.17M ﹤0.01% 4246
2025
Q1 		$7.07M Sell
425,470
-498,015
-54% -$9.05M ﹤0.01% 3021
2024
Q4 		$16.9M Buy
923,485
+249,366
+37% +$4.02M ﹤0.01% 2015
2024
Q3 		$10.4M Buy
674,119
+344,551
+105% +$5.75M ﹤0.01% 2568
2024
Q2 		$5.36M Buy
329,568
+156,465
+90% +$2.53M ﹤0.01% 3333
2024
Q1 		$3.2M Sell
173,103
-202,160
-54% -$5.01M ﹤0.01% 4397
2023
Q4 		$11.7M Buy
375,263
+52,883
+16% +$1.26M ﹤0.01% 2430
2023
Q3 		$6.72M Buy
322,380
+263,917
+451% +$7.17M ﹤0.01% 3084
2023
Q2 		$1.4M Sell
58,463
-171,797
-75% -$3.82M ﹤0.01% 5920
2023
Q1 		$4.33M Buy
230,260
+151,522
+192% +$2.89M ﹤0.01% 3665
2022
Q4 		$1.25M Sell
78,738
-112,852
-59% -$1.76M ﹤0.01% 5696
2022
Q3 		$3.13M Buy
191,590
+4,677
+3% +$75.7K ﹤0.01% 3998
2022
Q2 		$2.63M Buy
186,913
+75,430
+68% +$1.41M ﹤0.01% 4325
2022
Q1 		$2.7M Sell
111,483
-280,637
-72% -$6.79M ﹤0.01% 4823
2021
Q4 		$9.15M Buy
392,120
+78,180
+25% +$1.57M ﹤0.01% 2854
2021
Q3 		$5.21M Sell
313,940
-218,034
-41% -$4.2M ﹤0.01% 3872
2021
Q2 		$13M Buy
531,974
+290,358
+120% +$6.55M ﹤0.01% 2563
2021
Q1 		$6.23M Buy
241,616
+72,997
+43% +$3.21M ﹤0.01% 3500
2020
Q4 		$9.01M Sell
168,619
-53,303
-24% -$2.65M ﹤0.01% 2624
2020
Q3 		$9.15M Buy
221,922
+64,549
+41% +$2.79M ﹤0.01% 2279
2020
Q2 		$7.63M Buy
157,373
+81,940
+109% +$3.93M ﹤0.01% 2458
2020
Q1 		$3.19M Sell
75,433
-227,086
-75% -$9.36M ﹤0.01% 3193
2019
Q4 		$12.9M Buy
302,519
+43,147
+17% +$1.88M ﹤0.01% 1820
2019
Q3 		$9.34M Buy
259,372
+68,670
+36% +$2.08M ﹤0.01% 2051
2019
Q2 		$5.1M Buy
190,702
+137,607
+259% +$3.52M ﹤0.01% 2685
2019
Q1 		$1.43M Sell
53,095
-74,013
-58% -$1.73M ﹤0.01% 4320
2018
Q4 		$2.06M Buy
+127,108
New +$2.47M ﹤0.01% 3481
2018
Q2 		– Sell
-264,800
Closed -$4.72M – 9505
2018
Q1 		$5.95M Sell
264,800
-145,986
-36% -$4.04M ﹤0.01% 2330
2017
Q4 		$12.4M Sell
410,786
-96,151
-19% -$3.07M ﹤0.01% 1655
2017
Q3 		$19.1M Buy
506,937
+227,619
+81% +$7.4M 0.01% 1259
2017
Q2 		$7.79M Sell
279,318
-287,107
-51% -$8.56M ﹤0.01% 1917
2017
Q1 		$19.5M Buy
566,425
+195,665
+53% +$6.91M 0.01% 1086
2016
Q4 		$10.7M Buy
370,760
+72,103
+24% +$1.91M 0.01% 1498
2016
Q3 		$9.5M Sell
298,657
-181,346
-38% -$6.15M ﹤0.01% 1578
2016
Q2 		$15.6M Buy
480,003
+165,006
+52% +$5.52M 0.01% 1131
2016
Q1 		$8.81M Sell
314,997
-94,150
-23% -$2.05M ﹤0.01% 1679
2015
Q4 		$14.6M Sell
409,147
-157,932
-28% -$5.56M 0.01% 1413
2015
Q3 		$18.8M Buy
567,079
+22,202
+4% +$924K 0.01% 1261
2015
Q2 		$22.8M Buy
544,877
+118,122
+28% +$4.57M 0.01% 1192
2015
Q1 		$13.9M Sell
426,755
-589,046
-58% -$20.2M 0.01% 1552
2014
Q4 		$32.3M Buy
1,015,801
+390,565
+62% +$11.1M 0.01% 988
2014
Q3 		$15.5M Sell
625,236
-122,192
-16% -$2.86M 0.01% 1666
2014
Q2 		$16.9M Buy
747,428
+165,635
+28% +$3.46M 0.01% 1542
2014
Q1 		$14.2M Sell
581,793
-264,080
-31% -$6.68M 0.01% 1614
2013
Q4 		$21.1M Buy
845,873
+11,389
+1% +$269K 0.01% 1300
2013
Q3 		$22.9M Buy
834,484
+219,958
+36% +$4.6M 0.01% 1109
2013
Q2 		$11.2M Buy
+614,526
New +$8.46M 0.01% 1666

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Susquehanna International Group's ACAD Position: Q1 2026 in Review

Susquehanna International Group increased its Acadia Pharmaceuticals (ACAD) stake by 117% in Q1 2026, buying an estimated $577K and bringing the position to 44,792 shares worth $997K. The position accounts for ﹤0.01% of the portfolio, ranked #7897.

Susquehanna International Group first reported a position in ACAD in Q2 2013 and has held it in 50 quarters since. The position peaked at $32.3M in Q4 2014. 342 funds tracked by Wall St. Rank hold ACAD as of Q1 2026.

  • Susquehanna International Group held 44,792 shares of Acadia Pharmaceuticals worth $997K as of Q1 2026.
  • Susquehanna International Group bought 24,140 Acadia Pharmaceuticals shares in Q1 2026, an estimated $577K.
  • Acadia Pharmaceuticals made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #7897 holding.
  • Susquehanna International Group first reported a position in Acadia Pharmaceuticals in Q2 2013 and has held it in 50 quarters since.
  • Susquehanna International Group's Acadia Pharmaceuticals position peaked at $32.3M in Q4 2014.
  • 342 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.